FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
A phase 1 trial treated 15 patients with breast cancer that spread to the spinal fluid using a vaccine made from their own immune cells. One patient is now more than three years from diagnosis.